CVS Puts the GLP-1 Break-Even Price at $350 a Month

CVS Health put a number on the GLP-1 argument on November 15, 2026. In a white paper titled “GLP-1s: Good Drugs, High Prices,” the company said the medicines break even for employers and health plans at a net price of about $350 a month over three years. Above that price, the pharmacy bill outruns the medical savings. Below it, fewer hospital visits start paying for the prescriptions.

The analysis uses anonymized claims from Aetna, the insurer CVS owns, covering commercial fully insured members who started a GLP-1 between 2023 and 2025, with up to three years of follow-up. Researchers compared those patients with similar patients who didn't take the drugs. The medicines in the data include Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy, which mimic the GLP-1 hormone and reduce appetite.

The clinical side of the ledger is strong. GLP-1 use was associated with 10 to 12 percent fewer emergency room visits in the first and second years. Among about 4,000 patients still taking a drug after three years, hospitalizations ran 34 to 42 percent lower than among matched non-users. Those are associations in claims data, not results from a randomized trial, and CVS didn't break out figures for obesity patients alone.

The money side is where the current prices fail. Across three years, plan sponsors saved about $9,400 per person on medical bills and spent about $13,300 more per person on prescriptions. That's the gap the $350 figure is built to close: at today's prices the drugs add to total spending even while they keep people out of hospitals.

The prices on the ground show how far apart the market sits. Cash-pay customers can buy Zepbound for about $299 a month and Wegovy for about $349, close to the break-even line. Employers and other plan sponsors pay between $617 and $766 a month, according to a 2025 study by the Employee Benefit Research Institute that Reuters cited. The federal government has already negotiated lower: its deal with Lilly and Novo pays $245 a month for injectable weight-loss drugs in an 18-month Medicare pilot.

Coverage is moving the other way. Employers are dropping or restricting GLP-1 coverage for obesity as they face premium increases expected to top 9 percent in 2027. Dr. Amy Compton-Phillips, CVS Health's chief medical officer, argued ahead of the HLTH USA conference in Las Vegas that the drugmakers' own direct-to-consumer prices show they can still profit below $350 a month. “I hope that we can reach that price sooner rather than later,” she said.

CVS isn't a neutral referee here. It owns the insurer whose claims it analyzed, the pharmacy benefit business that negotiates these prices, and pharmacies that sell the drugs. Its number still matters because it's the first time a payer with data at this scale has published the price at which the savings and the spending cross.

What happens next is a negotiation, not a verdict. If plan prices drift toward the cash-pay level, the coverage cuts become harder to justify on cost alone. If they stay above $600, the study hands employers a documented reason to keep restricting drugs that their own insurer says work.